Opendata, web and dolomites

CTCapture_2.0 SIGNED

Advanced platform for profiling of therapeutic targets and functional analysis of circulating tumour cells in cancer patients

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "CTCapture_2.0" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF 

Organization address
address: Martinistrasse 52
city: HAMBURG
postcode: 20251
website: www.uke.uni-hamburg.de

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Total cost 149˙825 €
 EC max contribution 149˙825 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2016-PoC
 Funding Scheme ERC-POC
 Starting year 2017
 Duration (year-month-day) from 2017-05-01   to  2018-10-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITAETSKLINIKUM HAMBURG-EPPENDORF DE (HAMBURG) coordinator 149˙825.00

Map

 Project objective

As an alternative to invasive needle biopsies, the analysis of CTCs released by metastatic lesions into the blood has been recently introduced by the PI as “liquid biopsy”. The molecular analysis of CTCs before and during treatment could supply a real-time status of the landscape of metastatic tumor cell clones in an individual cancer patient. CTCs might reveal representative information on metastatic cells located at different sites because the blood represents a pool of tumor cells potentially released by all lesions in the cancer patients. Moreover, blood samples can be taken sequentially during the course of the disease and therefore allow a real-time assessment of the molecular evolution of the disease with important implications for decision making on cancer therapies. However, despite the obvious potential of CTCs as biomarker, current CTC capture assays require sophisticated, expensive and complex assay systems, which is the most important bottleneck for a more widespread use of CTCs as liquid biopsy. The assay development in the ERC PoC Grant CAPTURE-CTC (end: 11/2016) and the successful research on improved methods for molecular characterization of CTCs in the Advanced Investigator Grant DISSECT (end: 07/2016) of the PI has allowed to develop a novel improved platform for CTC detection. To implement our chip into future clinical decision making, we will now focus on the clinical validation of the chip platform including the development of SOPs as basis for kits for expression of therapeutic targets and resistance mechanisms in CTCs. Moreover, the establishment of transient CTC cultures from chip-isolated tumor cells will foster drug testing in individual cancer patients. In conclusion, the CTCapture_2.0 project will be an important prerequisite for successful future commercialization of a novel liquid biopsy assay.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "CTCAPTURE_2.0" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "CTCAPTURE_2.0" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

TotipotentZygotChrom (2020)

Mechanisms of chromatin organization and reprogramming in totipotent mammalian zygotes

Read More  

ArtHistCEE (2018)

Art Historiographies in Central and Eastern EuropeAn Inquiry from the Perspective of Entangled Histories

Read More  

DINEMOS (2019)

Discovery of New Molecular Semiconductors

Read More